Aquestive Therapeutics has made substantial progress, as detailed in its Q2 2026 earnings call, focusing primarily on the resubmission of Anaphylm. The company successfully completed crucial human factors and pharmacokinetic studies, addressing previous FDA concerns and reinforcing the product's clinical differentiation. Alongside this regulatory milestone, Aquestive reported significant financial improvements, including a 38% year-over-year revenue increase and a reduced adjusted EBITDA loss. The firm's strategic initiatives include a targeted launch of Anaphylm to the allergy community, continued development of the AdrenaVerse platform, and prudent cash management to support future growth and commercialization efforts.
During the recent Q2 2026 earnings conference call, Aquestive Therapeutics provided a comprehensive update on its operational and financial performance. A central theme was the imminent resubmission of Anaphylm, a sublingual epinephrine film designed for severe allergic reactions. Daniel Barber, President and CEO, emphasized the company's swift response to the FDA's Complete Response Letter (CRL), achieving resubmission readiness in less than eight months. This rapid turnaround was facilitated by successful human factors validation and pharmacokinetic (PK) studies. The human factors study demonstrated a marked improvement in user experience, with only one participant reporting difficulty opening the packaging and zero film tearing incidents, a significant reduction from previous figures. Additionally, dose misplacement decreased substantially, from 20 to just two participants.
The PK study further bolstered Anaphylm's profile, showing no statistical difference between clinician-administered and self-administered drug products. Notably, even in an intentionally misadministered scenario (film placed on top of the tongue), the drug elicited rapid and clinically meaningful pharmacodynamic responses, comparable to traditional intramuscular epinephrine injections. These findings are crucial for addressing FDA's concerns and building confidence among healthcare providers and payers. The company reiterated its belief in Anaphylm's potential to disrupt the epinephrine rescue market, which it estimates could reach $1 billion to $2 billion annually, driven by its ease of use, portability, and strong clinical differentiation compared to existing auto-injectors. This market segment has shown consistent 6% annual growth, indicating a robust demand for innovative solutions.
Aquestive's commercial strategy for Anaphylm is highly focused, targeting the allergy community at launch. Sherry Korczynski, Chief Commercial Officer, highlighted that allergists, who typically see patients annually for prescription renewals, represent an efficient pathway for market penetration. This targeted approach is expected to optimize cash burn while maximizing impact. Furthermore, the company discussed its AdrenaVerse platform, particularly AQST-108 for atopic dermatitis. Dr. Matthew Davis, Chief Development Officer, presented compelling preclinical data showing TSLP, CCL3, and CCL4 suppression, suggesting a novel approach to treating itch in atopic dermatitis. This localized topical application could offer a depot-like effect, potentially allowing for less frequent dosing and differentiating it from current low-cost generics and high-priced biologics.
Financially, Aquestive reported a total revenue of $13.8 million for Q2 2026, a 38% increase year-over-year, primarily due to higher manufacture and supply revenue from Suboxone and royalty payments from Zevra. The company also improved its non-GAAP adjusted EBITDA loss to $5.2 million, compared to $9.3 million in the prior year quarter, demonstrating enhanced financial discipline. Cash and cash equivalents stood at $98.5 million as of June 30, 2026, with an additional $75 million in launch funding expected from RTW and $20 million from Oaktree upon Anaphylm's FDA approval. These funds, combined with ongoing partnering discussions for Libervant and international Anaphylm rights, provide a strong liquidity position for future commercialization and pipeline expansion. Regulatory filings for Anaphylm in Canada and the European Union are planned for Q4 2026 and Q1 2027, respectively, signaling a broad international strategy. Despite potential FDA review timelines being at the agency's discretion, Aquestive remains optimistic about an expedited process given the concise nature of its resubmission package.
The second quarter of 2026 for Aquestive Therapeutics was marked by significant strides in both clinical development and financial management. The company is on the cusp of resubmitting its New Drug Application for Anaphylm, an oral epinephrine film, following successful human factors and pharmacokinetic studies that decisively addressed prior regulatory feedback. This progress positions Anaphylm as a potentially transformative treatment in the anaphylaxis market, characterized by a persistent need for more convenient and effective options than current auto-injectors. Aquestive's robust financial performance, including a notable increase in revenue and improved EBITDA, underscores its operational efficiency and strategic focus. With a clear path for Anaphylm's launch, the ongoing development of its AdrenaVerse platform, and a strong capital base, the company is well-prepared to execute its commercial strategy and explore new therapeutic areas.
